Cancer Research Meeting Calendar  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 11886, December 15, 2007. doi: 10.1158/0008-5472.CAN-07-2964
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Batista, L. F.Z.
Right arrow Articles by Kaina, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Batista, L. F.Z.
Right arrow Articles by Kaina, B.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating xpc, ddb2, and DNA Double-Strand Breaks

Luís F.Z. Batista1,2, Wynand P. Roos1, Markus Christmann1, Carlos F.M. Menck2 and Bernd Kaina1

1 Department of Toxicology, University of Mainz, Mainz, Germany and 2 Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil

Requests for reprints: Bernd Kaina, Department of Toxicology, University of Mainz, Obere Zahlbacher Strasse 67, D-55131 Mainz, Germany. Phone: 49-6131-393-3246; Fax: 49-6131-230506; E-mail: kaina{at}uni-mainz.de.

Glioblastoma multiforme is the most severe form of brain cancer. First line therapy includes the methylating agent temozolomide and/or the chloroethylating nitrosoureas [1-(2-chloroethyl)-1-nitrosourea; CNU] nimustine [1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea; ACNU], carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea; BCNU], or lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; CCNU]. The mechanism of cell death after CNU treatment is largely unknown. Here we show that ACNU and BCNU induce apoptosis in U87MG [p53 wild-type (p53wt)] and U138MG [p53 mutant (p53mt)] glioma cells. However, contrary to what we observed previously for temozolomide, chloroethylating drugs are more toxic for p53-mutated glioma cells and induce both apoptosis and necrosis. Inactivation of p53 by pifithrin-{alpha} or siRNA down-regulation sensitized p53wt but not p53mt glioma cells to ACNU and BCNU. ACNU and BCNU provoke the formation of DNA double-strand breaks (DSB) in glioma cells that precede the onset of apoptosis and necrosis. Although these DSBs are repaired in p53wt cells, they accumulate in p53mt cells. Therefore, functional p53 seems to stimulate the repair of CNU-induced cross-links and/or DSBs generated from CNU-induced lesions. Expression analysis revealed an up-regulation of xpc and ddb2 mRNA in response to ACNU in U87MG but not U138MG cells, indicating p53 regulates a pathway that involves these DNA repair proteins. ACNU-induced apoptosis in p53wt glioma cells is executed via both the extrinsic and intrinsic apoptotic pathway, whereas in p53mt glioma cells, the mitochondrial pathway becomes activated. The data suggest that p53 has opposing effects in gliomas treated with methylating or chloroethylating agents and, therefore, the p53 status should be taken into account when deciding which therapeutic drug to use. [Cancer Res 2007;67(24):11886–95]




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system
Mol. Cancer Ther., November 1, 2009; 8(11): 3140 - 3150.



Home page
Mol Cancer ResHome page
G. Frosina
DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy
Mol. Cancer Res., July 1, 2009; 7(7): 989 - 999.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
L. F.Z. Batista, W. P. Roos, B. Kaina, and C. F.M. Menck
p53 Mutant Human Glioma Cells Are Sensitive to UV-C-Induced Apoptosis Due to Impaired Cyclobutane Pyrimidine Dimer Removal
Mol. Cancer Res., February 1, 2009; 7(2): 237 - 246.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. B. Dinca, K. V. Lu, J. N. Sarkaria, R. O. Pieper, M. D. Prados, D. A. Haas-Kogan, S. R. VandenBerg, M. S. Berger, and C. D. James
p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts
Cancer Res., December 15, 2008; 68(24): 10034 - 10039.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. Yan, G. Liu, A. Scoumanne, and X. Chen
Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations
Cancer Res., August 15, 2008; 68(16): 6789 - 6796.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Monfared, A. Winkeler, M. Klein, H. Li, A. Klose, M. Hoesel, Y. Waerzeggers, S. Korsching, and A. H. Jacobs
Noninvasive Assessment of E2F-1-Mediated Transcriptional Regulation In vivo
Cancer Res., July 15, 2008; 68(14): 5932 - 5940.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.